{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:14:48Z","timestamp":1769721288876,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study sought to determine the relationship between cervical cancer recurrence and post-treatment change in standardized uptake value (SUV) of 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) in the cervix and lymph nodes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients who received curative intent radiation therapy for biopsy-proven stage I\u2013IVA locally advanced cervical cancer at a single tertiary referral center from 2009 to 2021. The exposure was percent change in SUV from pre- to post-treatment FDG-PET scans at the cervix and lymph nodes. The primary outcome was recurrence rate, and secondary outcomes were overall and progression-free survival. Firth\u2019s penalized logistic regression and Cox proportional hazards models were used to assess associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      55 patients met eligibility criteria. Recurrence rate was 27% (15\/55); of these, 33% had local recurrence (5\/55) and 67% had distant recurrence (10\/55). Median percent decrease of cervical SUV after treatment in those with and without recurrence was similar (71.4 vs 68.8,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.89); this remained consistent when analyzing those with local recurrence only (70.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.95). When the percent decrease in cervical SUV was examined in intervals (&lt;\u200925%, 25\u201350%, 50\u201375%,\u2009&gt;\u200975%), this was also not predictive of local (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.91) or overall (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.75) recurrence. Median percent decrease at the most avid and distant lymph node in those with and without recurrence was not significantly different (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Neither change in cervical nor lymph node SUV was associated with overall or progression-free survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Changes in SUV after treatment may not be a reliable stand-alone marker for predicting recurrence or survival in locally advanced cervical cancer after treatment with radiation therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-026-08330-5","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:14:20Z","timestamp":1769681660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of FDG-PET SUV changes in cervical cancer following radiation therapy: a retrospective cohort study"],"prefix":"10.1007","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-7066","authenticated-orcid":false,"given":"Claudia A.","family":"Bale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janina V.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipankar","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nophar","family":"Yarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Sport","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devin T.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Fields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie A.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"3","key":"8330_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1470-2045(19)30072-5","volume":"20","author":"M Brisson","year":"2019","unstructured":"Brisson M, Drolet M (2019) Global elimination of cervical cancer as a public health problem. Lancet Oncol 20(3):319\u2013321. https:\/\/doi.org\/10.1016\/S1470-2045(19)30072-5","journal-title":"Lancet Oncol"},{"key":"8330_CR2","volume-title":"Cervical Cancer in StatPearls","author":"JR Fowler","year":"2022","unstructured":"Fowler JR, Maani EV, Dunton CJ, Gasalberti DP, Jack BW (2022) Cervical Cancer in StatPearls. StatPearls Publishing, Florida"},{"issue":"1","key":"8330_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ijgo.12969","volume":"145","author":"N Bhatla","year":"2019","unstructured":"Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, Kehoe ST, Konishi I, Olawaiye AB, Prat J, Sankaranarayanan R, Brierley J, Mutch D, Querleu D, Cibula D, Quinn M, Botha H, Sigurd L, Rice L, Ryu HS, Ngan H, M\u00e4enp\u00e4\u00e4 J, Andrijono A, Purwoto G, Maheshwari A, Bafna UD, Plante M, Natarajan J (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129\u2013135. https:\/\/doi.org\/10.1002\/ijgo.12969","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"8330_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cpet.2017.11.004","volume":"13","author":"C Viswanathan","year":"2018","unstructured":"Viswanathan C, Faria S, Devine C, Patnana M, Sagebiel T, Iyer RB, Bhosale PR (2018) [18F]-2-fluoro-2-deoxy-D-glucose-PET assessment of cervical cancer. PET Clin 13(2):165\u2013177. https:\/\/doi.org\/10.1016\/j.cpet.2017.11.004","journal-title":"PET Clin"},{"issue":"12","key":"8330_CR5","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1136\/ijgc-2022-003801","volume":"32","author":"BJ Monk","year":"2022","unstructured":"Monk BJ, Tan DSP, Hern\u00e1ndez Chag\u00fci JD, Takyar J, Paskow MJ, Nunes AT, Pujade-Lauraine E (2022) Proportions and incidence of locally advanced cervical cancer: a global systematic literature review. Int J Gynecol Cancer 32(12):1531\u20131539. https:\/\/doi.org\/10.1136\/ijgc-2022-003801","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"8330_CR6","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e66","volume":"30","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Han S, Kim YS, Nam JH (2019) Prognostic value of post-treatment 1\u2078F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis. J Gynecol Oncol 30(5):e66. https:\/\/doi.org\/10.3802\/jgo.2019.30.e66","journal-title":"J Gynecol Oncol"},{"issue":"11","key":"8330_CR7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1200\/JCO.2004.09.035","volume":"22","author":"PW Grigsby","year":"2004","unstructured":"Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I (2004) Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 22(11):2167\u20132171. https:\/\/doi.org\/10.1200\/JCO.2004.09.035","journal-title":"J Clin Oncol"},{"issue":"4","key":"8330_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/s0360-3016(02)04287-6","volume":"55","author":"PW Grigsby","year":"2003","unstructured":"Grigsby PW, Siegel BA, Dehdashti F, Mutch DG (2003) Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 55(4):907\u2013913. https:\/\/doi.org\/10.1016\/s0360-3016(02)04287-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"8330_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00259-015-3112-8","volume":"42","author":"S Siva","year":"2015","unstructured":"Siva S, Deb S, Young RJ, Hicks RJ, Callahan J, Bressel M, Mileshkin L, Rischin D, Bernshaw D, Narayan K (2015) 1\u2078F-FDG PET\/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. Eur J Nucl Med Mol Imaging 42(12):1825\u20131832. https:\/\/doi.org\/10.1007\/s00259-015-3112-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"8330_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137743","volume":"10","author":"GO Chong","year":"2015","unstructured":"Chong GO, Jeong SY, Park SH, Lee YH, Lee SW, Hong DG, Kim JC, Lee YS, Cho YL (2015) Comparison of the prognostic value of F-18 pet metabolic parameters of primary tumors and regional lymph nodes in patients with locally advanced cervical cancer who are treated with concurrent chemoradiotherapy. PLoS ONE 10(9):e0137743. https:\/\/doi.org\/10.1371\/journal.pone.0137743","journal-title":"PLoS ONE"},{"issue":"7","key":"8330_CR11","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00259-018-3957-8","volume":"45","author":"FY Liu","year":"2018","unstructured":"Liu FY, Su TP, Wang CC, Chao A, Chou HH, Chang YC, Yen TC, Lai CH (2018) Roles of posttherapy (18)F-FDG PET\/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging 45(7):1197\u20131204. https:\/\/doi.org\/10.1007\/s00259-018-3957-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8330_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13014-016-0614-x","volume":"11","author":"FG Herrera","year":"2016","unstructured":"Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M (2016) [(18)F]FDG-PET\/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol 11:43. https:\/\/doi.org\/10.1186\/s13014-016-0614-x","journal-title":"Radiat Oncol"},{"issue":"6","key":"8330_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1097\/IGC.0b013e31821dc8b5","volume":"21","author":"C Kunos","year":"2011","unstructured":"Kunos C, Radivoyevitch T, Abdul-Karim FW, Faulhaber P (2011) 18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response. Int J Gynecol Cancer 21(6):1117\u20131123. https:\/\/doi.org\/10.1097\/IGC.0b013e31821dc8b5","journal-title":"Int J Gynecol Cancer"},{"issue":"19","key":"8330_CR14","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1001\/jama.298.19.2289","volume":"298","author":"JK Schwarz","year":"2007","unstructured":"Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW (2007) Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298(19):2289\u20132295. https:\/\/doi.org\/10.1001\/jama.298.19.2289","journal-title":"JAMA"},{"issue":"2","key":"8330_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1006\/gyno.2001.6504","volume":"84","author":"Y Nakamoto","year":"2002","unstructured":"Nakamoto Y, Eisbruch A, Achtyes ED, Sugawara Y, Reynolds KR, Johnston CM, Wahl RL (2002) Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol 84(2):289\u2013295. https:\/\/doi.org\/10.1006\/gyno.2001.6504","journal-title":"Gynecol Oncol"},{"issue":"2","key":"8330_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.semradonc.2011.12.009","volume":"22","author":"AH Klopp","year":"2012","unstructured":"Klopp AH, Eifel PJ (2012) Biological predictors of cervical cancer response to radiation therapy. Semin Radiat Oncol 22(2):143\u2013150. https:\/\/doi.org\/10.1016\/j.semradonc.2011.12.009","journal-title":"Semin Radiat Oncol"},{"issue":"11","key":"8330_CR17","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1002\/1097-0142(19910601)67:11<2776::AID-CNCR2820671111>3.0.CO;2-L","volume":"67","author":"FB Stehman","year":"1991","unstructured":"Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC (1991) Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 67(11):2776\u20132785","journal-title":"Cancer"},{"issue":"2 Pt 1","key":"8330_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0090-8258(81)90145-1","volume":"12","author":"J Boyce","year":"1981","unstructured":"Boyce J, Fruchter RG, Nicastri AD, Ambiavagar PC, Reinis MS, Nelson JH Jr. (1981) Prognostic factors in stage I carcinoma of the cervix. Gynecol Oncol 12(2 Pt 1):154\u2013165. https:\/\/doi.org\/10.1016\/0090-8258(81)90145-1","journal-title":"Gynecol Oncol"},{"issue":"9596","key":"8330_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/JS9.0000000000000940","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, STROBE Initiative (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20131457. https:\/\/doi.org\/10.1097\/JS9.0000000000000940","journal-title":"Lancet"},{"issue":"10","key":"8330_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, STROBE Initiative (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 4(10):e297. https:\/\/doi.org\/10.1371\/journal.pmed.0040297","journal-title":"PLoS Med"},{"issue":"7","key":"8330_CR21","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1097\/IGC.0b013e31829ee012","volume":"23","author":"Q Zhao","year":"2013","unstructured":"Zhao Q, Feng Y, Mao X, Qie M (2013) Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography or PET-computed tomography in cervical cancer: a meta-analysis. Int J Gynecol Cancer 23(7):1184\u20131190. https:\/\/doi.org\/10.1097\/IGC.0b013e31829ee012","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"8330_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/RLU.0000000000001049","volume":"41","author":"A Sarker","year":"2016","unstructured":"Sarker A, Im HJ, Cheon GJ, Chung HH, Kang KW, Chung JK, Kim EE, Lee DS (2016) Prognostic implications of the SUVmax of primary tumors and metastatic lymph node measured by 18F-FDG PET in patients with uterine cervical cancer: a meta-analysis. Clin Nucl Med 41(1):34\u201340. https:\/\/doi.org\/10.1097\/RLU.0000000000001049","journal-title":"Clin Nucl Med"},{"issue":"1","key":"8330_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ygyno.2015.01.542","volume":"137","author":"C Onal","year":"2015","unstructured":"Onal C, Guler OC, Reyhan M, Yapar AF (2015) Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy. Gynecol Oncol 137(1):40\u201346","journal-title":"Gynecol Oncol"},{"issue":"3","key":"8330_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00259-007-0612-1","volume":"35","author":"TC Yen","year":"2008","unstructured":"Yen TC, See LC, Lai CH, Tsai CS, Chao A, Hsueh S, Hong JH, Chang TC, Ng KK (2008) Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging 35(3):493\u2013501","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"8330_CR25","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.2009.25.4151","volume":"28","author":"EA Kidd","year":"2010","unstructured":"Kidd EA, Siegel BA, Dehdashti F, Grigsby PW (2010) Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 28(13):2108\u20132113","journal-title":"J Clin Oncol"},{"issue":"9","key":"8330_CR26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s00066-022-01900-x","volume":"198","author":"S Pedraza","year":"2022","unstructured":"Pedraza S, Seiffert AP, Sarandeses P, Mu\u00f1oz-Lopez B, G\u00f3mez EJ, S\u00e1nchez-Gonz\u00e1lez P, P\u00e9rez-Regadera JF (2022) The value of metabolic parameters and textural analysis in predicting prognosis in locally advanced cervical cancer treated with chemoradiotherapy. Strahlenther Onkol 198(9):792\u2013801. https:\/\/doi.org\/10.1007\/s00066-022-01900-x","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"8330_CR27","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2214\/AJR.18.19734","volume":"211","author":"S Han","year":"2018","unstructured":"Han S, Kim H, Kim YJ, Suh CH, Woo S (2018) Prognostic value of volume-based metabolic parameters of (18)F-FDG PET\/CT in uterine cervical cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 211(5):1112\u20131121. https:\/\/doi.org\/10.2214\/AJR.18.19734","journal-title":"AJR Am J Roentgenol"},{"key":"8330_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11120809","author":"P Cegla","year":"2021","unstructured":"Cegla P, Hofheinz F, Cholewi\u0144ski W, Czepczy\u0144ski R, Kubiak A, van den Hoff J, Bo\u015b-Liedke A, Roszak A, Burchardt E (2021) Prognostic value of pretherapeutic primary tumor MTV from [(18)F]FDG PET in radically treated cervical cancer patients. Metabolites. https:\/\/doi.org\/10.3390\/metabo11120809","journal-title":"Metabolites"},{"issue":"4","key":"8330_CR29","doi-asserted-by":"publisher","first-page":"908","DOI":"10.2214\/AJR.19.21604","volume":"214","author":"DF Pinho","year":"2020","unstructured":"Pinho DF, King B, Xi Y, Albuquerque K, Lea J, Subramaniam RM (2020) Value of intratumoral metabolic heterogeneity and quantitative (18)F-FDG PET\/CT parameters in predicting prognosis for patients withCervical cancer. AJR Am J Roentgenol 214(4):908\u2013916. https:\/\/doi.org\/10.2214\/AJR.19.21604","journal-title":"AJR Am J Roentgenol"},{"issue":"16","key":"8330_CR30","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.1158\/1078-0432.CCR-07-5252","volume":"14","author":"EA Kidd","year":"2008","unstructured":"Kidd EA, Grigsby PW (2008) Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res 14(16):5236\u20135241. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5252","journal-title":"Clin Cancer Res"},{"issue":"10","key":"8330_CR31","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1200\/JCO.22.01096","volume":"1","author":"MP Schmid","year":"2023","unstructured":"Schmid MP, Lindegaard JC, Mahantshetty U, Tanderup K, J\u00fcrgenliemk-Schulz I, Haie-Meder C, Fokdal LU, Sturdza A, Hoskin P, Segedin B, Bruheim K, Huang F, Rai B, Cooper R, van der Steen-Banasik E, Van Limbergen E, Pieters BR, Petric P, Ramazanova D, Ristl R, Kannan S, Hawaldar R, Ecker S, Kirchheiner K, Tan LT, Nout R, Nesvacil N, de Leeuw A, P\u00f6tter R, Kirisits C, EMBRACE Collaborative Group (2023) Risk factors for local failure following chemoradiation and magnetic resonance image-guided brachytherapy in locally advanced cervical cancer: results from the EMBRACE-I study. J Clin Oncol 1(10):1933\u20131942. https:\/\/doi.org\/10.1200\/JCO.22.01096","journal-title":"J Clin Oncol"},{"key":"8330_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110199","volume":"194","author":"C Hui","year":"2024","unstructured":"Hui C, Ewongwo A, Mendoza MG, Kozak MM, Jackson S, Fu J, Kidd E (2024) Less than whole uterus irradiation for patients with locally advanced cervical cancer. Radiother Oncol 194:110199. https:\/\/doi.org\/10.1016\/j.radonc.2024.110199","journal-title":"Radiother Oncol"},{"issue":"5","key":"8330_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101817","volume":"35","author":"J Lee","year":"2025","unstructured":"Lee J, Lin JB, Wang CH, Lin WH, Chang CL, Chen YJ (2025) Whole-uterine versus individualized-uterine radiotherapy in locally advanced cervical cancer: clinical outcome and toxicity. Int J Gynecol Cancer 35(5):101817. https:\/\/doi.org\/10.1016\/j.ijgc.2025.101817","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"8330_CR34","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","volume":"22","author":"R P\u00f6tter","year":"2021","unstructured":"P\u00f6tter R, Tanderup K, Schmid MP, J\u00fcrgenliemk-Schulz I, Haie-Meder C, Fokdal LU, Sturdza AE, Hoskin P, Mahantshetty U, Segedin B, Bruheim K, Huang F, Rai B, Cooper R, van der Steen-Banasik E, Van Limbergen E, Pieters BR, Tan LT, Nout RA, De Leeuw AAC, Ristl R, Petric P, Nesvacil N, Kirchheiner K, Kirisits C, Lindegaard JC, EMBRACE Collaborative Group (2021) MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 22(4):538\u2013547. https:\/\/doi.org\/10.1016\/S1470-2045(20)30753-1","journal-title":"Lancet Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-026-08330-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-026-08330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T10:14:21Z","timestamp":1769681661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-026-08330-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8330"],"URL":"https:\/\/doi.org\/10.1007\/s00404-026-08330-5","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was performed at a single-site urban, safety net, tertiary referral institution with National Cancer Institute (NCI) designation following public registration of the investigation (researchregistry10267) and institutional review board approval (IRB HM20024055).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was conducted as a retrospective review of existing medical records following institutional review board approval (IRB HM20024055). As a retrospective chart review study that involved no direct patient contact and minimal risk to subjects, a waiver of informed consent was granted by the IRB in accordance with institutional policies. All patient data were de-identified during analysis and reporting to protect patient privacy, with no identifying information included in the manuscript. No images of patients were used in this publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"66"}}